pcDNA3-SARS-CoV-2-S-RBD-Fc Citations (12)
Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4. PubMed Journal
Articles Citing pcDNA3-SARS-CoV-2-S-RBD-Fc
| Articles |
|---|
| The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. Procko E. bioRxiv. 2020 May 11. doi: 10.1101/2020.03.16.994236. PubMed |
| Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naive semisynthetic library. Parray HA, Chiranjivi AK, Asthana S, Yadav N, Shrivastava T, Mani S, Sharma C, Vishwakarma P, Das S, Pindari K, Sinha S, Samal S, Ahmed S, Kumar R. J Biol Chem. 2020 Sep 4;295(36):12814-12821. doi: 10.1074/jbc.AC120.014918. Epub 2020 Jul 29. PubMed |
| Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Gowda P, Patrick S, Joshi SD, Kumawat RK, Sen E. Cytokine. 2021 Jun;142:155496. doi: 10.1016/j.cyto.2021.155496. Epub 2021 Mar 12. PubMed |
| Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi AK, Mani S, Bansal M, Dwivedi P, Shrivastava T, Kumar R, Awasthi A, Ahmed S, Samal S. Front Immunol. 2021 Mar 26;12:613045. doi: 10.3389/fimmu.2021.613045. eCollection 2021. PubMed |
| Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, Awasthi A, Surjit M. Front Immunol. 2021 May 24;12:641447. doi: 10.3389/fimmu.2021.641447. eCollection 2021. PubMed |
| Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. Murugavelu P, Perween R, Shrivastava T, Singh V, Ahmad Parray H, Singh S, Chiranjivi AK, Thiruvengadam R, Singh S, Yadav N, Jakhar K, Sonar S, Mani S, Bhattacharyya S, Sharma C, Vishwakarma P, Khatri R, Kumar Panchal A, Das S, Ahmed S, Samal S, Kshetrapal P, Bhatnagar S, Luthra K, Kumar R. Int Immunopharmacol. 2021 Oct;99:108020. doi: 10.1016/j.intimp.2021.108020. Epub 2021 Jul 29. PubMed |
| The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. Perween R, PraveenKumar M, Shrivastava T, Parray HA, Singh V, Singh S, Chiranjivi A, Jakhar K, Sonar S, Tiwari M, Reema, Panchal AK, Sharma C, Rathore DK, Ahamed S, Samal S, Mani S, Bhattacharyya S, Das S, Luthra K, Kumar R. Int Immunopharmacol. 2021 Dec;101(Pt B):108187. doi: 10.1016/j.intimp.2021.108187. Epub 2021 Sep 28. PubMed |
| Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2. Castiglione GM, Zhou L, Xu Z, Neiman Z, Hung CF, Duh EJ. PLoS Biol. 2021 Dec 21;19(12):e3001510. doi: 10.1371/journal.pbio.3001510. eCollection 2021 Dec. PubMed |
| Characterization of a broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2. Garg S, Raj N, Lukose A, Jamwal D, Parray HA, Kumar S, Dhyani S, Jakhar K, Sonar S, Tiwari M, Reema, Mani S, Bhattacharyya S, Sharma C, Shrivastava T, Kumar R. 3 Biotech. 2022 Sep;12(9):202. doi: 10.1007/s13205-022-03272-6. Epub 2022 Aug 2. PubMed |
| Sortase A transpeptidation produces seamless, unbranched biotinylated nanobodies for multivalent and multifunctional applications. Obeng EM, Steer DL, Fulcher AJ, Wagstaff KM. Nanoscale Adv. 2023 Mar 15;5(8):2251-2260. doi: 10.1039/d3na00014a. eCollection 2023 Apr 11. PubMed |
| Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections. Mani S, Kaur A, Jakhar K, Kumari G, Sonar S, Kumar A, Das S, Kumar S, Kumar V, Kundu R, Pandey AK, Singh UP, Majumdar T. Int J Biol Macromol. 2023 Aug 1;245:125444. doi: 10.1016/j.ijbiomac.2023.125444. Epub 2023 Jun 27. PubMed |
| MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis. Pydyn N, Ferenc A, Trzos K, Pospiech E, Wilamowski M, Mucha O, Major P, Kadluczka J, Rodrigues PM, Banales JM, Herranz JM, Avila MA, Hutsch T, Malczak P, Radkowiak D, Budzynski A, Jura J, Kotlinowski J. Cell Mol Gastroenterol Hepatol. 2024;17(6):887-906. doi: 10.1016/j.jcmgh.2024.01.021. Epub 2024 Feb 3. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.